Literature DB >> 1707057

Adhesive properties of the beta 3 integrins: comparison of GP IIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells.

N Kieffer1, L A Fitzgerald, D Wolf, D A Cheresh, D R Phillips.   

Abstract

Glycoprotein IIb-IIIa (alpha IIb beta 3) and the vitronectin receptor (alpha v beta 3), two integrins that share the common beta 3 subunit, have been reported to function as promiscuous receptors for the RGD-containing adhesive proteins fibrinogen, vitronectin, fibronectin, von Willebrand factor, and thrombospondin. The present study was designed to establish a cell system for the expression of either GP IIb-IIIa or the vitronectin receptor in an otherwise identical cellular environment and to compare the adhesive properties of these two integrins with those of native GP IIb-IIIa and the vitronectin receptor constitutively expressed in HEL cells or platelets. M21 human melanoma cells lack GP IIb-IIIa and use the vitronectin receptor to attach to vitronectin, fibrinogen, fibronectin, and von Willebrand factor. To study the functional properties of GP IIb-IIIa in these cells, we transfected GP IIb into M21-L cells, a variant of M21 cells (Cheresh, D.A., and R.C. Spiro. 1987. J. Biol. Chem. 262:17703-17711), which lack the expression of functional alpha v and are therefore unable to attach to vitronectin, fibrinogen, and von Willebrand factor. Transfectants expressing GP IIb were isolated by immunomagnetic beads and surface expression of the GP IIb-IIIa complex was documented by FACS analysis and immunoprecipitation experiments performed with 125I-labeled M21-L/GP IIb cells. Comparative functional studies demonstrated that GP IIb-IIIa expressed in M21-L/GPIIb cells as well as native GP IIb-IIIa constitutively expressed in HEL-5J20 cells (an HEL variant lacking alpha v beta 3) mediated cell attachment to immobilized fibrinogen, but not to vitronectin or von Willebrand factor, whereas the vitronectin receptor expressed in M21 cells and HEL-AD1 cells (an HEL variant expressing alpha v beta 3) mediated cell attachment to fibrinogen, vitronectin, and von Willebrand factor. Similarly, PGl2-treated resting platelets attached to immobilized fibrinogen but not to vitronectin or von Willebrand factor, and this attachment could be inhibited by mAb A2A9 (directed against a functional site on the GP IIb-IIIa complex). However, in contrast to platelets, which adhered to vitronectin and von Willebrand factor after stimulation by thrombin or PMA, activation of the protein kinase C pathway in M21-L/GP IIb or HEL cells did not induce cell adhesion to vitronectin or von Willebrand factor.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707057      PMCID: PMC2288943          DOI: 10.1083/jcb.113.2.451

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  53 in total

1.  THE PREPARATION AND SOME PROPERTIES OF FIBRINOGEN PRECIPITATED FROM HUMAN PLASMA BY GLYCINE.

Authors:  L A KAZAL; S AMSEL; O P MILLER; L M TOCANTINS
Journal:  Proc Soc Exp Biol Med       Date:  1963 Aug-Sep

2.  SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.

Authors:  Y Takebe; M Seiki; J Fujisawa; P Hoy; K Yokota; K Arai; M Yoshida; N Arai
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

Review 3.  New perspectives in cell adhesion: RGD and integrins.

Authors:  E Ruoslahti; M D Pierschbacher
Journal:  Science       Date:  1987-10-23       Impact factor: 47.728

Review 4.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

5.  Multiple very late antigen (VLA) heterodimers on platelets. Evidence for distinct VLA-2, VLA-5 (fibronectin receptor), and VLA-6 structures.

Authors:  M E Hemler; C Crouse; Y Takada; A Sonnenberg
Journal:  J Biol Chem       Date:  1988-06-05       Impact factor: 5.157

6.  The human fibroblast class II extracellular matrix receptor mediates platelet adhesion to collagen and is identical to the platelet glycoprotein Ia-IIa complex.

Authors:  T J Kunicki; D J Nugent; S J Staats; R P Orchekowski; E A Wayner; W G Carter
Journal:  J Biol Chem       Date:  1988-04-05       Impact factor: 5.157

Review 7.  The platelet membrane glycoprotein IIb-IIIa complex.

Authors:  D R Phillips; I F Charo; L V Parise; L A Fitzgerald
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

8.  Thrombin enhanced adhesion of platelets to von Willebrand factor substrates.

Authors:  S A Santoro; J F Cowan
Journal:  Thromb Res       Date:  1986-07-01       Impact factor: 3.944

9.  Platelet interaction with polymerizing fibrin.

Authors:  S Niewiarowski; E Regoeczi; G J Stewart; A F Senyl; J F Mustard
Journal:  J Clin Invest       Date:  1972-03       Impact factor: 14.808

10.  Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression.

Authors:  Z Werb; P M Tremble; O Behrendtsen; E Crowley; C H Damsky
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

View more
  20 in total

1.  A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.

Authors:  F Lanza; A Stierlé; D Fournier; M Morales; G André; A T Nurden; J P Cazenave
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

2.  Evidence that integrin alpha IIb beta 3-dependent interaction of mast cells with fibrinogen exacerbates chronic inflammation.

Authors:  Toshihiko Oki; Koji Eto; Kumi Izawa; Yoshinori Yamanishi; Naoki Inagaki; Jon Frampton; Toshio Kitamura; Jiro Kitaura
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

3.  Transmembrane-truncated alphavbeta3 integrin retains high affinity for ligand binding: evidence for an 'inside-out' suppressor?

Authors:  R J Mehta; B Diefenbach; A Brown; E Cullen; A Jonczyk; D Güssow; G A Luckenbach; S L Goodman
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

4.  Trans-dominant inhibition of integrin function.

Authors:  F Díaz-González; J Forsyth; B Steiner; M H Ginsberg
Journal:  Mol Biol Cell       Date:  1996-12       Impact factor: 4.138

5.  Constitutive activation of integrin alpha 4 beta 1 defines a unique stage of human thymocyte development.

Authors:  D R Salomon; C F Mojcik; A C Chang; S Wadsworth; D H Adams; J E Coligan; E M Shevach
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

6.  Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins.

Authors:  C Marcinkiewicz; L A Rosenthal; D M Mosser; T J Kunicki; S Niewiarowski
Journal:  Biochem J       Date:  1996-08-01       Impact factor: 3.857

7.  Down-regulation of alpha v/beta 3 integrin via misrouting to lysosomes by overexpression of a beta 3Lamp1 fusion protein.

Authors:  Magali Conesa; Annik Prat; John S Mort; Jacques Marvaldi; Jean-Claude Lissitzky; Nabil G Seidah
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

8.  The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3.

Authors:  Steven B Ludbrook; Simon T Barry; Chris J Delves; Carmel M T Horgan
Journal:  Biochem J       Date:  2003-01-15       Impact factor: 3.857

9.  Ser-752-->Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia.

Authors:  Y P Chen; I Djaffar; D Pidard; B Steiner; A M Cieutat; J P Caen; J P Rosa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Kistrin, an integrin antagonist, blocks endocytosis of fibrinogen into guinea pig megakaryocyte and platelet alpha-granules.

Authors:  P Handagama; D F Bainton; Y Jacques; M T Conn; R A Lazarus; M A Shuman
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.